Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05189223

A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatment

Led by VA Office of Research and Development ยท Updated on 2025-07-17

50

Participants Needed

1

Research Sites

186 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The US Veteran community continues to feel the impact of the overdose crisis, and opioid use disorder (OUD) diagnoses among Veterans continue to rise. Medication treatment (e.g., buprenorphine, methadone, naltrexone) helps prevent relapse and reduce overdose risk, but does not help with the psychological, social, and functional challenges of early recovery. Therapies that focus on interpersonal functioning and community integration may help improve quality of life during this high-risk period. This research project will create and test a brief, values-based treatment to help Veterans improve their interpersonal functioning and community integration during early treatment. This study will have three phases. Phase 1 will involve the development of the treatment and adaptation using interviews with Veterans and VA Providers. Phase 2 will test the treatment with a group of 10 Veterans to make sure the treatment can be delivered as intended, and to make changes to the treatment or study procedures based on Veteran feedback. Finally, Phase 3 will test the treatment compared to usual treatment in a pilot randomized controlled trial with a group of 40 Veterans. This final phase will provide additional information about Veterans' experience of the treatment and study procedures and the preliminary effects of the treatment on quality of life and related outcomes.

CONDITIONS

Official Title

A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatment

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Meets current Diagnostic and Statistical Manual - 5th Edition criteria for moderate to severe opioid use disorder
  • Within 12 weeks of starting buprenorphine, methadone, or naltrexone treatment after at least 2 months without treatment
  • Able to provide written informed consent
Not Eligible

You will not qualify if you...

  • Active psychosis or mania
  • Suicidal thoughts requiring inpatient hospitalization
  • Active substance use needing detoxification
  • Cognitive impairment interfering with study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

VA Bedford HealthCare System, Bedford, MA

Bedford, Massachusetts, United States, 01730-1114

Actively Recruiting

Loading map...

Research Team

V

Victoria Ameral, PhD

CONTACT

A

Anne Marie Hernon

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here